153 related articles for article (PubMed ID: 38055253)
1. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN; Angelergues A; Konecny GE; García Y; Banerjee S; Lorusso D; Lee JY; Moroney JW; Colombo N; Roszak A; Tromp J; Myers T; Lee JW; Beiner M; Cosgrove CM; Cibula D; Martin LP; Sabatier R; Buscema J; Estévez-García P; Coffman L; Nicum S; Duska LR; Pignata S; Gálvez F; Wang Y; Method M; Berkenblit A; Bello Roufai D; Van Gorp T;
N Engl J Med; 2023 Dec; 389(23):2162-2174. PubMed ID: 38055253
[TBL] [Abstract][Full Text] [Related]
2. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Moore KN; Oza AM; Colombo N; Oaknin A; Scambia G; Lorusso D; Konecny GE; Banerjee S; Murphy CG; Tanyi JL; Hirte H; Konner JA; Lim PC; Prasad-Hayes M; Monk BJ; Pautier P; Wang J; Berkenblit A; Vergote I; Birrer MJ
Ann Oncol; 2021 Jun; 32(6):757-765. PubMed ID: 33667670
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
[TBL] [Abstract][Full Text] [Related]
4. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
[TBL] [Abstract][Full Text] [Related]
6. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM
Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
[TBL] [Abstract][Full Text] [Related]
9. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
Moore KN; Vergote I; Oaknin A; Colombo N; Banerjee S; Oza A; Pautier P; Malek K; Birrer MJ
Future Oncol; 2018 Jul; 14(17):1669-1678. PubMed ID: 29424243
[TBL] [Abstract][Full Text] [Related]
10. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G; Coleman RL; Vergote I; van Gorp T; Ray-Coquard I; Oaknin A; Matulonis U; O'Malley D; Raspagliesi F; Scambia G; Monk BJ
Int J Gynecol Cancer; 2024 Apr; 34(4):469-477. PubMed ID: 38101816
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis.
Wang Y; Liu L; Jin X; Yu Y
Crit Rev Oncol Hematol; 2024 Feb; 194():104230. PubMed ID: 38122916
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies targeting folate receptor α for ovarian cancer.
Mai J; Wu L; Yang L; Sun T; Liu X; Yin R; Jiang Y; Li J; Li Q
Front Immunol; 2023; 14():1254532. PubMed ID: 37711615
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA; Lorusso D; Oaknin A; Pignata S; Dean A; Denys H; Colombo N; Van Gorp T; Konner JA; Marin MR; Harter P; Murphy CG; Wang J; Noble E; Esteves B; Method M; Coleman RL
J Clin Oncol; 2023 May; 41(13):2436-2445. PubMed ID: 36716407
[TBL] [Abstract][Full Text] [Related]
14. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
[TBL] [Abstract][Full Text] [Related]
15. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A; Shah M; Ison G; Gittleman H; Fiero MH; Shah A; Hamed SS; Qiu J; Yu J; Manheng W; Ricks TK; Pragani R; Arudchandran A; Patel P; Zaman S; Roy A; Kalavar S; Ghosh S; Pierce WF; Rahman NA; Tang S; Mixter BD; Kluetz PG; Pazdur R; Amiri-Kordestani L
Clin Cancer Res; 2023 Oct; 29(19):3835-3840. PubMed ID: 37212825
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis.
Xu K; Wang T; Pan S; He J
Expert Rev Clin Pharmacol; 2023; 16(11):1141-1152. PubMed ID: 37771164
[TBL] [Abstract][Full Text] [Related]
18. Mirvetuximab Soravtansine: First Approval.
Heo YA
Drugs; 2023 Feb; 83(3):265-273. PubMed ID: 36656533
[TBL] [Abstract][Full Text] [Related]
19. Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
Nwabufo CK
Cancer Chemother Pharmacol; 2024 Feb; 93(2):89-105. PubMed ID: 37594572
[TBL] [Abstract][Full Text] [Related]
20. Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
Fowler M
Oncology (Williston Park); 2020 Jul; 34(7):250. PubMed ID: 32674207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
